\odot

GMP API REG WDA	A GDP Sites	
		Wed 24 Feb 2021 10:
mpliance Menu		
<u>tificates</u> <u>pliance Report</u>	Print Preview Print Preview (Short version)	Back To Search
	National Agency for Medicines and Medical	
	CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTUR	CERTIFICATE NUMBER :005/20
	Part 1	
	Issued following an inspection in accordance with :	
	Art. 15 of Directive 2001/20/EC	
	The competent authority of Romania confirms the following:	
	The manufacturer : INFOMED FLUIDS S.R.L.	
	Site address : Str. Theodor Pallady nr. 50, sector 3, Bucureşti, cod 032266, Romania	
	Has been inspected under the national inspection programme in connection with manufacturing autho Directive 2001/20/EC transposed in the following national legislation: art. 48 from Minister of Public Health Order no. 904/2006 for approval of Regulations relating the imple conduct of clinical trials on medicinal products of human use	
	From the knowledge gained during inspection of this manufacturer, the latest of which was conducted o with :	n 2018-09-28 , it is considered that it complie
	 The principles and guidelines of Good Manufacturing Practice laid down in Directive 2003/94/EC (3) 	
	The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the	ie ieeung aanonig.
	 The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/8 from third countries into a Member State. Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP datab These requirements fulfil the GMP recommendations of WHO. 	
	from third countries into a Member State. (2) Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP datab	
	from third countries into a Member State. (2) Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP datab (3) These requirements fulfil the GMP recommendations of WHO.	
	from third countries into a Member State. (2) Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP datab (3) These requirements fulfil the GMP recommendations of WHO. Part 2	
	from third countries into a Member State. (2) Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP datab (3) These requirements fulfil the GMP recommendations of WHO. Part 2 Human Investigational Medicinal Products	
	from third countries into a Member State. (2) Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP datab (3) These requirements fulfil the GMP recommendations of WHO. Part 2 Human Investigational Medicinal Products 1 MANUFACTURING OPERATIONS	
	from third countries into a Member State. (2) Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP datab (3) These requirements fulfil the GMP recommendations of WHO. Part 2 Human Investigational Medicinal Products 1 MANUFACTURING OPERATIONS 1.1 Sterile products 1.1.2 Terminally Sterilised (processing operations for the following dosage forms) 1.1.2.1 Large volume liquids	
	from third countries into a Member State. (2) Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP datab (3) These requirements fulfil the GMP recommendations of WHO. Part 2 Human Investigational Medicinal Products 1 MANUFACTURING OPERATIONS 1.1 Sterile products 1.1.2 Terminally Sterilised (processing operations for the following dosage forms) 1.1.2.1 Large volume liquids 1.1.3 Batch certification	
	from third countries into a Member State. (2) Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP datab (3) These requirements fulfil the GMP recommendations of WHO. Part 2 Human Investigational Medicinal Products 1 MANUFACTURING OPERATIONS 1.1 Sterile products 1.1.2 Terminally Sterilised (processing operations for the following dosage forms) 1.1.2.1 Large volume liquids 1.1.3 Batch certification 1.5 Packaging	
	from third countries into a Member State. (2) Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP datab (3) These requirements fulfil the GMP recommendations of WHO. Part 2 Human Investigational Medicinal Products 1 MANUFACTURING OPERATIONS 1.1 Sterile products 1.1.2 Terminally Sterilised (processing operations for the following dosage forms) 1.1.2.1 Large volume liquids 1.1.3 Batch certification 1.5 Packaging 1.5.2 Secondary packaging	
	from third countries into a Member State. (2) Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP datab (3) These requirements fulfil the GMP recommendations of WHO. Part 2 Human Investigational Medicinal Products 1 MANUFACTURING OPERATIONS 1.1 Sterile products 1.1.2 Terminally Sterilised (processing operations for the following dosage forms) 1.1.2.1 Large volume liquids 1.1.3 Batch certification 1.5 Packaging 1.5.2 Secondary packaging 1.6.1 Microbiological: sterility 1.6.2 Microbiological: non-sterility 1.6.3 Chemical/Physical	ase.
	from third countries into a Member State. (2) Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP datability of the GMP recommendations of WHO. Part 2 Human Investigational Medicinal Products 1 MANUFACTURING OPERATIONS 1.1 Sterile products 1.1.2 Terminally Sterilised (processing operations for the following dosage forms) 1.1.2.1 Large volume liquids 1.1.3 Batch certification 1.5 Packaging 1.5.2 Secondary packaging 1.6.1 Microbiological: sterility 1.6.2 Microbiological: non-sterility 1.6.3 Chemical/Physical 1.6.4 Biological Clarifying remarks (for public users) : total manufacturing operations for sterile products – large volumes parenteral – terminally steril	ase.
	from third countries into a Member State. (2) Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP datability of the GMP recommendations of WHO. Part 2 Human Investigational Medicinal Products 1 MANUFACTURING OPERATIONS 1.1 Sterile products 1.1.2 Terminally Sterilised (processing operations for the following dosage forms) 1.1.2.1 Large volume liquids 1.1.3 Batch certification 1.5 Packaging 1.5.2 Secondary packaging 1.6.1 Microbiological: sterility 1.6.2 Microbiological: non-sterility 1.6.3 Chemical/Physical 1.6.4 Biological Clarifying remarks (for public users) : total manufacturing operations for sterile products – large volumes parenteral – terminally steril	ase.
	from third countries into a Member State. (2) These requirements fulfil the GMP recommendations of WHO. Part 2 Human Investigational Medicinal Products 1 MANUFACTURING OPERATIONS 1.1 Sterile products 1.1.2 Terminally Sterilised (processing operations for the following dosage forms) 1.1.2.1 Large volume liquids 1.3 Batch certification 1.5 Secondary packaging 1.5.2 Secondary packaging 1.6.1 Microbiological: sterility 1.6.2 Microbiological: sterility 1.6.2 Microbiological: sterility 1.6.3 Chemical/Physical 2019-01-16 Name and signature of the authorised person of the Confidential	ase.
	from third countries into a Member State. (2) Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP datable (3) These requirements fulfil the GMP recommendations of WHO. Part 2 Human Investigational Medicinal Products 1 MANUFACTURING OPERATIONS 1 MANUFACTURING OPERATIONS 1.1 Sterile products 1.1.2 Terminally Sterilised (processing operations for the following dosage forms) 1.1.2.1 Large volume liquids 1.3.3 Batch certification 1.5 Packaging 1.5.2 Secondary packaging 1.5.2 Secondary packaging 1.6.1 Microbiological: sterility 1.6.2 Microbiological: sterility 1.6.3 Chemical/Physical 1.6.4 Biological 1.6.4 Biological 1.6.4 Biological 1.6.4 Biological 1.6.4 Biological	ase.

The EudraGMDP database is maintained and operated by the EMA. Access to the general public is granted in order to enhance availability of information related to the EMA mandate. The content of the database is

provided by the National Competent Authorities (NCA) of the EEA. For this reason, the EMA accepts no responsibility or liability whatsoever (including but not limited to any direct or consequential loss or damage it might occur to you and/or any other third party) arising out of or in connection with the information on this database. Any questions about the content should be addressed to the relevant NCA. Please <u>click here</u> to get list of NCA's.

Due to the restrictions caused by COVID-19, the period of validity of MIA's, WDA's, GMP and GDP certificates is automatically extended until the end of 2021. On-site inspections will resume as soon as there is a consensus that the period of the public health crisis has passed. The clarifying remark section of individual MIA's, WDA's, GMP and GDP certificates will indicate any exceptions. Competent authorities reserve the right to inspect a manufacturing site should the need arise.

For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI

[EMA © 2014. EudraGMDP 6.4.9.4 build 2021/01/28 15:49]